Holen Sie sich die Stockscreener-App
0.293
5.02%
0.014
Handel nachbörslich:
.30
0.007
+2.39%
Schlusskurs vom Vortag:
$0.279
Offen:
$0.294
24-Stunden-Volumen:
264.07K
Relative Volume:
0.02
Marktkapitalisierung:
$12.24M
Einnahmen:
$20.27M
Nettoeinkommen (Verlust:
$-63.80M
KGV:
-0.1928
EPS:
-1.52
Netto-Cashflow:
$-68.35M
1W Leistung:
-4.00%
1M Leistung:
-26.75%
6M Leistung:
-38.28%
1J Leistung:
-70.99%
1-Tages-Spanne:
$0.2849
$0.30
1-Wochen-Bereich:
$0.2604
$0.3151
52-Wochen-Spanne:
$0.1417
$1.27
Carisma Therapeutics Inc Stock (CARM) Company Profile
Firmenname
Carisma Therapeutics Inc
Sektor
Branche
Telefon
(267) 491-6422
Adresse
3675 MARKET STREET, PHILADELPHIA
Vergleichen Sie CARM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.293 | 11.51M | 20.27M | -63.80M | -68.35M | -1.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-04-11 | Eingeleitet | BTIG Research | Buy |
| 2023-10-03 | Eingeleitet | CapitalOne | Overweight |
| 2023-07-06 | Eingeleitet | Evercore ISI | Outperform |
| 2023-05-31 | Hochstufung | Jefferies | Hold → Buy |
| 2023-05-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Carisma Therapeutics Inc Aktie (CARM) Neueste Nachrichten
Is Carisma Therapeutics Inc. stock bottoming outWeekly Profit Report & Fast Moving Market Watchlists - Newser
Is this a good reentry point in Carisma Therapeutics Inc.Forecast Cut & AI Based Buy and Sell Signals - Newser
Can Carisma Therapeutics Inc. Overcome Bearish SentimentMarket Momentum Signal Generator Shows Trends - beatles.ru
Carisma Therapeutics Approves Reverse Stock Split - The Globe and Mail
CARISMA Therapeutics 2025 Q1 Earnings Loss Narrows by 51.2% - AInvest
CARISMA Therapeutics: D. Boral Capital maintains Buy, PT raised to $1 from $0.90 - AInvest
Carisma Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Carisma Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Is it the right time to buy Carisma Therapeutics Inc. stockFree Market Volatility Navigation Tips - Jammu Links News
Is Carisma Therapeutics Inc. a good long term investmentCapitalize on market momentum for maximum gains - Jammu Links News
How many analysts rate Carisma Therapeutics Inc. as a “Buy”Capitalize on emerging investment opportunities - Jammu Links News
Why is Carisma Therapeutics Inc. stock attracting strong analyst attentionExplosive capital appreciation - Jammu Links News
How volatile is Carisma Therapeutics Inc. stock compared to the marketDynamic profit expansion - Jammu Links News
Published on: 2025-08-04 00:00:30 - Jammu Links News
Is Carisma Therapeutics Inc. stock overvalued or undervaluedIdentify winners with top-tier analysis - Jammu Links News
Does Carisma Therapeutics Inc. stock perform well during market downturnsOutstanding stock performance - Jammu Links News
What drives Carisma Therapeutics Inc. stock priceBuild a diversified portfolio for steady growth - Jammu Links News
Is Carisma Therapeutics Inc. a growth stock or a value stockExponentially increasing returns - Jammu Links News
Published on: 2025-08-02 00:52:36 - metal.it
How does Carisma Therapeutics Inc. compare to its industry peersFree Stock Target Finder That Work - Jammu Links News
What institutional investors are buying Carisma Therapeutics Inc. stockWealth Building Guidance For Smart Trading - jammulinksnews.com
What is the dividend policy of Carisma Therapeutics Inc. stockBest Dividend Tracker For Every Investor - Jammu Links News
Carisma Therapeutics Inc. stock daily chart insightsMomentum Based Equity Trading Plans Reviewed - metal.it
Carisma Therapeutics Inc. stock outlook for YEARMarket Momentum and Signal Alerts Suggest Reversal - metal.it
Will Carisma Therapeutics Inc. Benefit From Sector TailwindsBuy Low Sell High Stock Watch Strategy in Focus - metal.it
What makes Carisma Therapeutics Inc. stock price move sharplyValue Investing Picks With Stability Outlined - metal.it
Why Carisma Therapeutics Inc. stock attracts strong analyst attentionInvestment Strategy Designed for Capital Protection - metal.it
Moving Average Crossover Confirms Uptrend in Carisma Therapeutics Inc.Watchlist for Low Risk High Return Stocks Updated - metal.it
Published on: 2025-07-28 21:04:54 - metal.it
Applying big data sentiment scoring on Carisma Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser
Carisma Therapeutics Inc. stock outlook for YEAR Short-Term Profit Alert With Entry Forecast - Newser
Carisma Therapeutics Inc. (NASDAQ:CARM) Receives $1.93 Average Target Price from Brokerages - Defense World
Top Risks to Consider Before Buying Carisma Therapeutics Inc. StockHigh Return Investment Tips - Newser
Has Carisma Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewFree Popular Stock Recommendations - Newser
Key External Factors That Drive Carisma Therapeutics Inc. Stock Price MovementsQuick Profit Idea Stream - Newser
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of Shareholders - GlobeNewswire Inc.
How high can Carisma Therapeutics Inc. stock price go in 2025Triple-digit returns - Jammu Links News
Published on: 2025-07-25 09:50:28 - PrintWeekIndia
Finanzdaten der Carisma Therapeutics Inc-Aktie (CARM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):